Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
0.4027
-0.1056 (-20.78%)
Mar 31, 2025, 2:25 PM EDT - Market open
Sensei Biotherapeutics Stock Forecast
SNSE's stock price has decreased by -61.9% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Sensei Biotherapeutics stock have an average target of 4.25, with a low estimate of 4.00 and a high estimate of 5.00. The average target predicts an increase of 955.38% from the current stock price of 0.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Sensei Biotherapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Oppenheimer | Oppenheimer | Buy Maintains $3.5 → $4 | Buy | Maintains | $3.5 → $4 | +893.30% | Mar 28, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +893.30% | Mar 28, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +893.30% | Jan 10, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +893.30% | Jan 8, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +893.30% | Aug 7, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.73
from -1.20
EPS Next Year
-0.53
from -0.73
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | ||
Avg | n/a | n/a | n/a | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.46 | -0.27 | -1.47 | ||
Avg | -0.73 | -0.53 | -1.43 | ||
Low | -0.93 | -0.69 | -1.37 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.